Clinical trials: Vision
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
- Trial name
- VISIONARY-MS (NCT03536559)
- Testing
- CNM-Au8
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Clene Nanomedicine
Dry Eye Syndrome
An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry Eye
The purpose of this study is to evaluate the effect of acute and repeat dosing of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in a population of dry eye patients.
- Trial name
- NCT01223040
- Testing
- SYSTANE® Balance Lubricant Eye Drops
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Cataract
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
- Trial name
- NCT05550350
- Testing
- Dexycu
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Optic Neuritis
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
The main objective of the study is to determine whether glatiramer acetate 20 mg once daily reduces the amount of axonal loss in the optic nerve after a first event of acute optic neuritis compared to placebo patients and to…
- Trial name
- NCT00856635
- Testing
- Glatiramer Acetate
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Amblyopia
Luminopia One Pilot Study
A single-arm, multi-center, open-label pilot study to evaluate the feasibility, safety, and efficacy of the Luminopia One digital therapeutic in improving visual acuity in a pediatric amblyopia population.
- Trial name
- NCT02782117
- Testing
- Luminopia One
- Where
- 9 sites in United States
- Volunteers
- 84 people
- Sponsor
- Luminopia
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of Xalatan in Patients
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
- Trial name
- A6111128 (NCT00950690)
- Testing
- Xalatan 0.005% eye drops
- Where
- 3 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 1,289 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Myopia
Effects of Projected Peripheral Defocus on Ocular Biometrics
Acucela Inc. intends to develop a medical device to significantly halt or reverse myopic progression, which is a significant public health concern across the world, especially in Asian demographics.
- Trial name
- NCT04388020
- Testing
- Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field, Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone.
- Trial name
- NCT01292460
- Where
- 2 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Santen Oy
Alcohol Impairment, Nystagmus
Alcohol Impairment Detection in Healthy Adult Users With the Gaize Device
This study evaluates the effectiveness of the Gaize virtual reality headset as a non-invasive tool for detecting alcohol-related impairment through ophthalmic and neurological indicators.
- Conditions
- Alcohol Impairment, Nystagmus, Virtual Reality, Lack of Smooth Pursuit
- Trial name
- AAI (NCT07126938)
- Testing
- Alcoholic beverage
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gaize
Cataract
Ocular Biodistribution Study for Topically Applied ESBA105
The purpose of this study is to determine whether ESBA105, a single-chain (scFv) antibody against TNF-alpha, efficiently penetrates into the anterior chamber and the vitreous body upon topical administration to the eye.
- Trial name
- NCT00820014
- Where
- 2 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- ESBATech AG
Weight Loss
Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist
The purpose of this pilot study is to demonstrate the anatomical modulation of subcutaneous fat across the waist and hips that occurs through application of the Erchonia® ML Scanner (MLS) Laser manufactured for non-invasive body…
- Trial name
- NCT01292564
- Testing
- Erchonia MLS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Ocular Physiology
Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock
This will be a single-visit, randomized, double-masked, bilateral wear, non-dispensing, 2-sequence × 2-period crossover study to evaluate subject reported ocular symptoms.
- Trial name
- NCT05713552
- Testing
- Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock, Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Retinal Dystrophies, Color Vision Defects
Natural History Study of Inherited Retinal Diseases
This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal…
- Conditions
- Retinal Dystrophies, Color Vision Defects, Vision Disorders, Macular Degeneration
- Trial name
- MojiLVCDT (NCT07085533)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhongmou Therapeutics
Metastatic Breast Cancer
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
This multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period is to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxicity in cancer patients…
- Trial name
- NCT04983238
- Testing
- BYON5667 & SYD985
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Byondis B.V.
Open-Angle Glaucoma, Ocular Hypertension
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly…
- Trial name
- NCT01309204
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, Brinzolamide 1% ophthalmic suspension
- Volunteers
- 1,184 people
- Sponsor
- Alcon Research
Healthy Volunteers, Cardiometabolic Diseases
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
This study is testing NNC0705-0002, a new medicine that is being developed for conditions where inflammation may contribute to heart and metabolic health problems.
- Trial name
- NCT07797855
- Testing
- NNC0705-0002
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open-angle Glaucoma
Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma
The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.
- Trial name
- NCT00451152
- Testing
- Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Open Angle Glaucoma -Ocular Hypertension
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
Primary Objective: To assess the local and systemic safety and tolerability of ascending repeated topical doses of SAR366234 monotherapy in patients with open angle glaucoma (OAG) or ocular hypertension (OHT) as compared to…
- Trial name
- NCT02531152
- Testing
- Latanoprost, SAR366234
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi